Zai Lab intends to use the net proceeds from this offering for general corporate purposes. Goldman Sachs (Asia) L.L.C., ...

On Wednesday, Lexicon Pharmaceuticals Inc (LXRX) stock saw a decline, ending the day at $1.09 which represents a decrease of $-0.10 or -8.40% from the prior close of $1.19. The stock opened at $1.18 ...

On Wednesday, Talkspace Inc (TALK) stock saw a decline, ending the day at $3.3 which represents a decrease of $-0.07 or -2.08% from the prior close of $3.37. The stock opened at $3.42 and touched a ...

Hims & Hers Health Inc. shares tumbled 22% Thursday, on concerns that Amazon.com Inc.'s latest push into healthcare will disrupt Hims & Hers' business.

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company’s ...

Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com launched a rival service that offers upfront pricing ...

Fintel reports that on November 13, 2024, Leerink Partners downgraded their outlook for 908 Devices (NasdaqGM:MASS) from ...

Other equities analysts also recently issued research reports about the company. Leerink Partnrs raised Tectonic Therapeutic to a “strong-buy” rating in a research report on Wednesday, July 24th.

HC Wainwright reissued their neutral rating on shares of Zura Bio (NASDAQ:ZURA – Free Report) in a report released on Monday ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Leerink lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $19 from $20 and keeps an Outperform rating on the shares. The ...